Drug screening was performed with a custom panel of 42 small molecule drugs selected based on standard-of-care chemotherapies, drugs targeting common cancer genes and pathways for LGSOC, and the genomic profile of the patient’s tumor, which included a CHEK2 mutation and several VUSs (Fig. 1c). The gene discussed is CHEK2; the disease is neoplasm.